On May 26, 2020 DaVita Inc. (NYSE: DVA) ("DaVita") reported the pricing of its previously announced private offering of $1.75 billion aggregate principal amount of senior notes due 2030 (the "2030 notes") (Press release, DaVita, MAY 26, 2020, View Source [SID1234558499]). The 2030 notes were priced at 100% of their face amount to yield a 4.625% coupon. The offering is expected to close on June 9, 2020, subject to satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DaVita intends to use the net proceeds from the offering of the 2030 notes, together with cash on hand, to redeem all $1.75 billion aggregate principal amount outstanding of its 5.125% senior notes due 2024 (the "2024 notes") and pay all fees and expenses related to such redemption and the offering. The 2024 notes will be redeemed on July 15, 2020, subject to the completion of the 2030 notes offering. Nothing contained in this release constitutes a notice of redemption of the 2024 notes.

The 2030 notes were offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to certain non-U.S. persons in transactions outside the United States in compliance with Regulation S under the Securities Act. The offer and sale of the 2030 notes have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

This release does not constitute an offer to sell or the solicitation of an offer to buy the 2030 notes, nor will there be any sale of the 2030 notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

On May 26, 2020 Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, reported that it will present data from ongoing research using a blood-based methylation assay for cancer detection during the 2020 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Virtual Scientific Program held May 29-31, 2020 (Press release, Nucleix, MAY 26, 2020, View Source [SID1234558498]). The six-marker assay serves as an initial component of Nucleix’s screening tests generating significant signal in early cancers and leveraging existing, low-cost PCR technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Monitoring methylation changes in tumors that shed circulating cell-free DNA demonstrates an alternative approach to identifying many cancers, particularly at early stages, with just a handful of markers that are measured using the power of our proprietary EpiCheck technology," said Chris Hibberd, chief executive officer of Nucleix. "We have already seen success with this platform, having discovered, developed and launched a bladder cancer recurrence test kit in Europe and advanced a new test for patients at high-risk for lung cancer based on encouraging results seen with a disease specific panel. We look forward to sharing updates on the promising data supporting our Lung EpiCheck for patients at high risk for lung cancer."

Details are as follows:

Title: Discovery of a core-panel of markers for a blood-assay for cancer detection utilizing cfDNA methylation changes (#1522)
Presenter: Dr. Lasika Seneviratne, SCORA/LA Cancer Network

On May 26, 2020 Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") reported that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming investor conferences as follows (Press release, Eagle Pharmaceuticals, MAY 26, 2020, View Source [SID1234558497]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference:

Jefferies Virtual Healthcare Conference

Date:

Thursday, June 4, 2020

Time:

1:00 p.m. ET

Webcast:

View Source

Conference:

William Blair Virtual 40th Annual Growth Stock Conference

Date:

Thursday, June 11, 2020

Time:

10:00 a.m. CT / 11:00 a.m. ET

Webcast:

View Source

The presentations will be webcast live at the aforementioned times, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors section.

On May 26, 2020 Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") reported that it will present at the following two investor conferences in June (Press release, Medpace, MAY 26, 2020, View Source [SID1234558496]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Global Healthcare Conference
Date: Wednesday, June 3, 2020
Presentation: 8:30 a.m. ET
Speakers: August Troendle, President & Chief Executive Officer, Jesse Geiger, Chief Financial Officer & Chief Operating Officer, Laboratory Operations, and Kevin Brady, Executive Director of Finance

William Blair Virtual Annual Growth Stock Conference
Date: Tuesday, June 9, 2020
Presentation: 4:40 p.m. CT (5:40 p.m. ET)
Speakers: August Troendle, President & Chief Executive Officer, Jesse Geiger, Chief Financial Officer & Chief Operating Officer, Laboratory Operations, and Kevin Brady, Executive Director of Finance

A live webcast of the presentation will be accessible through the "Investors" section of the Company’s website at www.medpace.com and will be available for replay following the event.

On May 26, 2020 Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, reported its participation in an analyst-led fireside chat at the Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, at 10:00 a.m. ET (Press release, Alpine Immune Sciences, MAY 26, 2020, View Source [SID1234558495]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available online in the investor relations section of the company’s website at View Source A replay of the presentation will be available on the company website for 90 days following the webcast.